USPTO serial 87117832
MEDVU
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BUONGIORNO, CHRISTOPHER L
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MEDVU?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Toronto, Ontario, CA
Toronto, Ontario, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jorie L. Stroup
JORIE L. STROUP ROBERTS MLOTKOWSKI SAFRAN COLE & CALDERON, P.C.7918 JONES BRANCH DRIVESUITE 500MCLEAN, VA 22102Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Computer software for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes; computer software for the analysis of medical data, namely, medical imaging data, health care data, health records, medical records, genomic data, and environmental factors, for use in the prevention, diagnosis and treatment of medical conditions, analyzing clinical trials, analyzing drug interactions, development of vaccines and medicines, medical diagnostics, molecular medicine, precision medicine, and structural and functional analysis of genomes; computer software for use in the detection, identification, analysis, and classification of pathogens and toxins in a biological sample; computer software for the analysis of genomic data for use in tracking variation and mutation of pathogens; computer software featuring machine learning and deep learning algorithms for use in medical diagnostic testing, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, genetic testing for medical purposes, detection of pathogens and toxins in a biological sample, and molecular medicine, namely research, diagnosis and treatment of medical conditions on the basis of molecular mechanisms of disease; computer software for determining and predicting patterns in data, namely, medical data, genomic data, proteomic data, metabolomics data, transcriptomic data, nutritional and nutrigenomics data, medical imaging data, health care data, health records, medical records, genomic data, and environmental factor data; computer software for executing preconfigured non-field specific machine learning and deep learning algorithms and processes for the purposes of uploading and managing data for the training of preconfigured data models implemented on a hosted software platform utilizing said machine learning and deep learning processes and for utilizing said trained data models for determining and predicting patterns in said data | ACTIVE | — |
| 042 | Structural and functional analysis of genomes; research and development of vaccines and medicines; development of pharmaceutical preparations and medicines; providing software as a service (SaaS) for enabling others to access software for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, and genetic testing for medical purposes; providing software as a service (SaaS) for enabling others to access software for the analysis of medical data, namely, medical imaging data, health care data, health records, medical records, genomic data, and environmental factors, for use in the prevention, diagnosis and treatment of medical conditions, analyzing clinical trials, analyzing drug interactions, development of vaccines and medicines, medical diagnostics, molecular medicine, namely research, diagnosis and treatment of medical conditions on the basis of molecular mechanisms of disease, precision medicine, namely the customization and personalization of therapies and medical treatment practices for individual patients, and structural and functional analysis of genomes; providing software as a service (SaaS) for enabling others to access software for use in the detection, identification, analysis, and classification of pathogens and toxins in a biological sample; providing software as a service (SaaS) for enabling others to access software for the analysis of genomic data for use in tracking variation and mutation of pathogens; providing software as a service (SaaS) for enabling others to access and use machine learning and deep learning algorithms for use in medical diagnostics, medical image analysis, medical screening, medical testing, DNA screening for medical purposes, genetic testing for medical purposes, detection of pathogens and toxins in a biological sample, and molecular medicine, namely research, diagnosis and treatment of medical conditions on the basis of molecular mechanisms of disease; providing software as a service (SaaS) for enabling others to upload and manage data for determining and predicting patterns in the data, namely, medical data, genomic data, proteomic data, metabolomics data, transcriptomic data, nutritional and nutrigenomics data, medical imaging data, health care data, health records, medical records, genomic data, and environmental factors; providing software as a service (SaaS) for enabling others to upload and manage data for the training of data models by machine learning and deep learning processes | ACTIVE | — |
| 044 | Medical diagnostic services in the fields of infectious diseases, rheumatological diseases, cardiovascular diseases, respiratory diseases, endocrine diseases, neurological diseases, nephrological diseases, urological diseases, gynaecological diseases, obstetrical diseases, hematological diseases, gastroenterological diseases, neuropsychiatry, and oncology; Medical screening; Medical testing services in the fields of infectious diseases, rheumatological diseases, cardiovascular diseases, respiratory diseases, endocrine diseases, neurological diseases, nephrological diseases, urological diseases, gynaecological diseases, obstetrical diseases, hematological diseases, gastroenterological diseases, neuropsychiatry, and oncology; DNA screening for medical purposes; genetic testing for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SIGHTLINE INNOVATION INC.
- Other trademarks owned by SIGHTLINE INNOVATION INC.
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MEDVU
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 8, 2019 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 8, 2019 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 7, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 5, 2018 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 5, 2018 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 5, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 1, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 27, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 27, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 27, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 5, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 11, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 11, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 21, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 30, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 26, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 26, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 26, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 26, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 9, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 9, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 9, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 9, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 9, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 9, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 1, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 30, 2016 | NWAP | NEW APPLICATION ENTERED | — |